Abner Herrman & Brock Sours on Intuitive Surgical

Abner Herrman & Brock (AHB) reduced its stake in Intuitive Surgical (ISRG) by 9,629 shares, worth $4.62 million, during Q3 2025, a period when ISRG shares were underperforming the S&P 500. This divestment notably preceded ISRG's strong Q3 earnings report, which exceeded analyst expectations with a 20% increase in worldwide procedures. AHB's action, coupled with minor reductions in other healthcare tech holdings and increased exposure to big tech, suggests a strategic portfolio shift potentially reflecting a cautious stance on the healthcare technology sector.

Analysis

Abner Herrman & Brock (AHB) reduced its stake in Intuitive Surgical (ISRG) by 9,629 shares, valued at $4.62 million, during Q3 2025, decreasing its holding to 1.01% of its total AUM. This divestment occurred while ISRG shares were down 10.6% over the past year, underperforming the S&P 500 by 25.1 percentage points, driven by concerns over tariffs, Medicaid cuts, and increased competition.

Notably, AHB's sale preceded Intuitive Surgical's strong Q3 2025 earnings report, which subsequently beat analyst expectations for both revenue and earnings. The company reported a 20% year-over-year increase in worldwide procedures and robust demand for its new da Vinci 5 model, suggesting a positive operational trajectory post-Q3.

AHB's move appears to be part of a broader portfolio rebalancing, as the firm also slightly pared back positions in other healthcare technology companies like Stryker (SYK) and Abbott Laboratories (ABT). Concurrently, AHB increased its exposure to large-cap technology stocks including Nvidia (NVDA), Microsoft (MSFT), Amazon (AMZN), and Tesla (TSLA), indicating a potential strategic shift towards growth in the broader tech sector.

Key Decisions for Investors

• Investors should evaluate if AHB's divestment from ISRG and other healthcare tech, coupled with increased big tech exposure, signals a broader institutional reallocation away from certain healthcare segments.
• Given ISRG's strong Q3 earnings beat and 20% procedure growth, investors should reassess the company's fundamentals and growth prospects, potentially viewing the pre-earnings dip and AHB's sale as a mis-timed exit.
• While ISRG's operational performance is strong, investors should continue to monitor the impact of tariff concerns, potential Medicaid cuts, and competitive pressures on the healthcare technology sector, alongside ISRG's ability to maintain its innovation lead with products like da Vinci 5.